Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
What similarly acting projects are still unpartnered?
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
After a conference lacking the wow factor, biotech winners and losers emerge.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.